Benzinga | Nov 11, 2020 09:07AM EST

Champions Oncology Launches Autologous Tumor Infiltrating Lymphocyte Ex Vivo Platform

HACKENSACK, NJ / ACCESSWIRE / November 11, 2020 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global oncology technology solutions provider that is transforming drug discovery through innovative pharmacology, biomarker and data platforms, announced today the launch of a novel autologous immuno-oncology (IO) research platform. This autologous tumor infiltrating lymphocyte (TIL) ex vivo platform centers on the use of a tumor and an immune system derived from the same patient for investigations in the immuno-oncology space.